Kirk Kimmerling
Helping Healthcare Leaders and Partners Combat Biofilms, Infections and Diseases While Strengthen Immunity and Advance Mitochondrial Health | CEO & Founder, FiteBac Technology
- Role
- Founder CEO at Fitebac Technologies
- Location
- Marietta, GA, US
- LinkedIn followers
- 500 followers
About Kirk Kimmerling
The FiteBac Project\'s global research community is expanding, bringing together…
Experience
Founder CEO
Jun 2022 — Present · Marietta, GA, US
FiteBac Technology/FiteBac Pharma\'s innovations stem from the work of numerous international academic research scientists. FiteBac Pharma K21 is the blockbuster antimicrobial small molecule designed to modulate biological, immunological, and metabolic systems for treating a wide range of infectious and inflammatory diseases. This patented drug substance has demonstrated the ability to safely eliminate bacterial, fungal, and viral infections, enhance innate immunity, induce mitophagy while improving mitochondrial and cellular metabolism, accelerate wound healing, and even promote the development of zebrafish and chickens, leading to increased adult mass. Rigorous research from Dr. Bhupesh Prusty\'s laboratory and Dr Christopher Rongo\'s laboratory is focused on various aspects of mitochondrial remodeling and reprograming, as well as mitochondrial-to-nuclear signaling with K21. FiteBac K21 uniquely targets the underlying disease state, given that most diseases involve microbial-associated inflammation and mitochondrial dysfunction.
Find verified contacts for anyone on LinkedIn
Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.
Free plan included · No credit card required
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.